Neuroone Medical Technologies CORP Form 4 insider transactions

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, reports the acquisition of options to purchase 200,000 shares of common stock.

Christopher Volker, COO of NeuroOne Medical Technologies, acquired options to purchase 575,000 shares of common stock at an exercise price of $0.5796 on April 17, 2025.

Ronald W. McClurg, CFO of NeuroOne Medical Technologies, acquired options to purchase 250,000 shares of common stock on April 17, 2025, according to a Form 4 filing.

NeuroOne Medical Technologies CEO, David A. Rosa, acquired options to purchase 750,000 shares of common stock on April 17, 2025, at an exercise price of $0.5796.

Ronald W. McClurg, CFO of NeuroOne Medical Technologies, purchased 200,000 shares of common stock at $0.50 per share on April 4, 2025.

NeuroOne Medical Technologies CEO David A. Rosa purchased 100,000 shares of common stock at $0.50 per share on April 4, 2025.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 906 shares of common stock on March 31, 2025, to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 253 shares of common stock on March 31, 2025, to cover tax obligations.

NeuroOne Medical Technologies CEO David Rosa disposed of 2,458 shares of common stock on March 31, 2025, to cover tax obligations.

Chief Technology Officer Steve Mertens disposed of 7,376 shares of NeuroOne Medical Technologies Corp to satisfy tax obligations related to vesting restricted stock units.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 1,812 shares of common stock on February 18, 2025, to cover tax obligations.

David Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 71,325 shares of common stock on February 18, 2025, to satisfy tax obligations.

Director Paul Buckman reports acquisition of NeuroOne Medical Technologies stock and options through grants.

Director Edward Andrle of NeuroOne Medical Technologies Corp. reports receiving restricted stock units and options, signaling continued involvement with the company.

Director Jeffrey S. Mathiesen reports acquisition of NeuroOne Medical Technologies stock and options through grant and vesting.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, reported the disposal of 252 shares of common stock on January 31, 2025, to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies Corp, disposed of 90 shares of common stock on January 31, 2025, to cover tax obligations.

NeuroOne Medical Technologies CEO David Rosa disposed of 2,239 shares of common stock on January 31, 2025, to cover tax obligations arising from a previous transaction.

NeuroOne Medical Technologies' Chief Technology Officer, Steve Mertens, sold 1,158 shares of common stock on December 31, 2024, to cover tax obligations.

A NeuroOne Medical Technologies executive, Mark Christianson, sold 343 shares of common stock to cover tax obligations.

David Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 4,697 shares of common stock on December 31, 2024, to cover tax obligations.

NeuroOne Medical Technologies' Chief Technology Officer, Steve Mertens, sold 252 shares of common stock to cover tax obligations.

A NeuroOne Medical Technologies Business Development Director sold 90 shares of common stock to cover tax obligations.

NeuroOne Medical Technologies CEO, David A. Rosa, sold 2,239 shares of common stock to cover tax obligations.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 252 shares of common stock on October 31, 2024, to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 90 shares of common stock on October 31, 2024, to cover tax obligations.

NeuroOne Medical Technologies CEO David Rosa disposed of 2,239 shares of common stock on October 31, 2024, to cover tax obligations.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 1,158 shares of common stock on September 30, 2024, to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 343 shares of common stock to cover tax obligations.

NeuroOne Medical Technologies CEO David Rosa disposed of 4,697 shares of common stock on September 30, 2024, to cover tax obligations related to vested shares.